{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T15:06:28Z","timestamp":1778511988898,"version":"3.51.4"},"reference-count":74,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"vor","delay-in-days":450,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1093\/annonc\/mdy192","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T03:11:54Z","timestamp":1527131514000},"page":"1634-1657","source":"Crossref","is-referenced-by-count":947,"title":["4th ESO\u2013ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)"],"prefix":"10.1016","volume":"29","author":[{"given":"F.","family":"Cardoso","sequence":"first","affiliation":[]},{"given":"E.","family":"Senkus","sequence":"additional","affiliation":[]},{"given":"A.","family":"Costa","sequence":"additional","affiliation":[]},{"given":"E.","family":"Papadopoulos","sequence":"additional","affiliation":[]},{"given":"M.","family":"Aapro","sequence":"additional","affiliation":[]},{"given":"F.","family":"Andr\u00e9","sequence":"additional","affiliation":[]},{"given":"N.","family":"Harbeck","sequence":"additional","affiliation":[]},{"given":"B.","family":"Aguilar Lopez","sequence":"additional","affiliation":[]},{"given":"C.H.","family":"Barrios","sequence":"additional","affiliation":[]},{"given":"J.","family":"Bergh","sequence":"additional","affiliation":[]},{"given":"L.","family":"Biganzoli","sequence":"additional","affiliation":[]},{"given":"C.B.","family":"Boers-Doets","sequence":"additional","affiliation":[]},{"given":"M.J.","family":"Cardoso","sequence":"additional","affiliation":[]},{"given":"L.A.","family":"Carey","sequence":"additional","affiliation":[]},{"given":"J.","family":"Cort\u00e9s","sequence":"additional","affiliation":[]},{"given":"G.","family":"Curigliano","sequence":"additional","affiliation":[]},{"given":"V.","family":"Di\u00e9ras","sequence":"additional","affiliation":[]},{"given":"N.S.","family":"El Saghir","sequence":"additional","affiliation":[]},{"given":"A.","family":"Eniu","sequence":"additional","affiliation":[]},{"given":"L.","family":"Fallowfield","sequence":"additional","affiliation":[]},{"given":"P.A.","family":"Francis","sequence":"additional","affiliation":[]},{"given":"K.","family":"Gelmon","sequence":"additional","affiliation":[]},{"given":"S.R.D.","family":"Johnston","sequence":"additional","affiliation":[]},{"given":"B.","family":"Kaufman","sequence":"additional","affiliation":[]},{"given":"S.","family":"Koppikar","sequence":"additional","affiliation":[]},{"given":"I.E.","family":"Krop","sequence":"additional","affiliation":[]},{"given":"M.","family":"Mayer","sequence":"additional","affiliation":[]},{"given":"G.","family":"Nakigudde","sequence":"additional","affiliation":[]},{"given":"B.V.","family":"Offersen","sequence":"additional","affiliation":[]},{"given":"S.","family":"Ohno","sequence":"additional","affiliation":[]},{"given":"O.","family":"Pagani","sequence":"additional","affiliation":[]},{"given":"S.","family":"Paluch-Shimon","sequence":"additional","affiliation":[]},{"given":"F.","family":"Penault-Llorca","sequence":"additional","affiliation":[]},{"given":"A.","family":"Prat","sequence":"additional","affiliation":[]},{"given":"H.S.","family":"Rugo","sequence":"additional","affiliation":[]},{"given":"G.W.","family":"Sledge","sequence":"additional","affiliation":[]},{"given":"D.","family":"Spence","sequence":"additional","affiliation":[]},{"given":"C.","family":"Thomssen","sequence":"additional","affiliation":[]},{"given":"D.A.","family":"Vorobiof","sequence":"additional","affiliation":[]},{"given":"B.","family":"Xu","sequence":"additional","affiliation":[]},{"given":"L.","family":"Norton","sequence":"additional","affiliation":[]},{"given":"E.P.","family":"Winer","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"5","key":"10.1093\/annonc\/mdy192_bb0010","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.breast.2014.08.009","article-title":"ESO-ESMO 2nd International Consensus Guidelines for Advanced Breast Cancer (ABC2). Simultaneous publication in","volume":"23","author":"Cardoso","year":"2014","journal-title":"Breast"},{"key":"10.1093\/annonc\/mdy192_bb0015","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.breast.2018.03.002","article-title":"Global analysis of advanced\/metastatic breast cancer: decade report (2005\u20132015)","volume":"39","author":"Cardoso","year":"2018","journal-title":"Breast"},{"key":"10.1093\/annonc\/mdy192_bb0020","unstructured":"N Howlader, AM Noone, M Krapcho et al (eds). SEER Cancer Statistics Review, 1975\u20132013. Bethesda, MD: National Cancer Institute. http:\/\/seer.cancer.gov\/csr\/1975_2013\/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016."},{"key":"10.1093\/annonc\/mdy192_bb0025","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.breast.2016.10.005","article-title":"Improved survival in metastatic breast cancer 1985\u20132016","volume":"31","author":"Sundquist","year":"2017","journal-title":"Breast"},{"issue":"7","key":"10.1093\/annonc\/mdy192_bb0030","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00595-015-1252-x","article-title":"Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer","volume":"46","author":"Kobayashi","year":"2016","journal-title":"Surg Today"},{"key":"10.1093\/annonc\/mdy192_bb0035","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.breast.2017.05.014","article-title":"Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer\u2014results from the prospective German TMK cohort study","volume":"34","author":"Fietz","year":"2017","journal-title":"Breast"},{"issue":"2","key":"10.1093\/annonc\/mdy192_bb0040","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10549-017-4529-5","article-title":"Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990\u20132010","volume":"167","author":"Malmgren","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"10.1093\/annonc\/mdy192_bb0045","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00432-017-2428-0","article-title":"Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year results from the Munich Cancer Registry","volume":"143","author":"H\u00f6lzel","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdy192_bb0050","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-Magnitude of Clinical BenefitScale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdy192_bb0055","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1093\/annonc\/mdy192_bb0060","first-page":"244","article-title":"ESO-ESMO 3rd International Consensus Guidelines for Advanced Breast Cancer (ABC 3)","volume":"31","author":"Cardoso","year":"2017","journal-title":"Simultaneous publication in: Breast"},{"issue":"5","key":"10.1093\/annonc\/mdy192_bb0065","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s12282-015-0637-4","article-title":"Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer","volume":"23","author":"Noguchi","year":"2016","journal-title":"Breast Cancer"},{"issue":"2","key":"10.1093\/annonc\/mdy192_bb0070","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10549-010-1332-y","article-title":"Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer","volume":"126","author":"Masuda","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1093\/annonc\/mdy192_bb0075","doi-asserted-by":"crossref","first-page":"e000142","DOI":"10.1136\/esmoopen-2016-000142","article-title":"Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers","volume":"1","author":"Tabernero","year":"2017","journal-title":"ESMO Open"},{"key":"10.1093\/annonc\/mdy192_bb0080","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ejca.2016.10.023","article-title":"European Breast Cancer Conference manifesto on breast centres\/units","volume":"72","author":"Cardoso","year":"2017","journal-title":"Eur J Cancer"},{"issue":"Suppl 6","key":"10.1093\/annonc\/mdy192_bb0085","doi-asserted-by":"crossref","first-page":"vi160","DOI":"10.1093\/annonc\/mdt199","article-title":"Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Peccatori","year":"2013","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdy192_bb0090","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.fertnstert.2013.08.041","article-title":"Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion","volume":"100","author":"Ethics Committee of American Society for Reproductive Medicine","year":"2013","journal-title":"Fertil Steril"},{"issue":"19","key":"10.1093\/annonc\/mdy192_bb0095","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1200\/JCO.2013.49.2678","article-title":"Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"31","author":"Loren","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdy192_bb0100","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1634\/theoncologist.2016-0373","article-title":"Oncofertility: fertile ground for conflict between patient autonomy and medical values","volume":"22","author":"Walsh","year":"2017","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdy192_bb0105","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.breast.2016.12.004","article-title":"Why are guidelines not followed in clinical practice?","volume":"32","author":"Cardoso","year":"2017","journal-title":"Breast"},{"issue":"3","key":"10.1093\/annonc\/mdy192_bb0110","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.breast.2012.03.003","article-title":"1st International consensus guidelines for advanced breast cancer (ABC1)","volume":"21","author":"Cardoso","year":"2012","journal-title":"Breast"},{"issue":"10063","key":"10.1093\/annonc\/mdy192_bb0115","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1016\/S0140-6736(16)32389-3","article-title":"Fulvestrant 500mg versus anastrozole 1mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial","volume":"388","author":"Robertson","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1093\/annonc\/mdy192_bb0120","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of estrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1093\/annonc\/mdy192_bb0125","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1093\/annonc\/mdy192_bb0130","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"issue":"15 Suppl","key":"10.1093\/annonc\/mdy192_bb0135","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2017.35.15_suppl.1038","article-title":"Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2\u2013), advanced breast cancer (ABC)","volume":"35","author":"Hortobagyi","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4 Suppl","key":"10.1093\/annonc\/mdy192_bb0140","article-title":"First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the randomized phase III MONALEESA-7 trial","volume":"78","author":"Tripathy","year":"2018","journal-title":"Cancer Res"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdy192_bb0145","first-page":"mdx440.008","article-title":"236O_PR. MONARCH 3: abemaciclib as initial therapy for patients with HR+\/HER2- advanced breast cancer","volume":"28","author":"Di Leo","year":"2017","journal-title":"Ann Oncol"},{"issue":"15 Suppl","key":"10.1093\/annonc\/mdy192_bb0150","doi-asserted-by":"crossref","first-page":"TPS624","DOI":"10.1200\/jco.2015.33.15_suppl.tps624","article-title":"MONARCH 3: a randomized phase III study of anastrozole or letrozole plus abemaciclib, a CDK4\/6 inhibitor, or placebo in first-line treatment of women with HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC)","volume":"33","author":"Goetz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdy192_bb0155","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/annonc\/mdy012","article-title":"Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial","volume":"29","author":"Rugo","year":"2018","journal-title":"Ann Oncol"},{"issue":"15 Suppl","key":"10.1093\/annonc\/mdy192_bb0160","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2017.35.15_suppl.1020","article-title":"Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib + letrozole: results from MONALEESA-2","volume":"35","author":"Verma","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy192_bb0165","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/S0960-9776(17)30684-7","article-title":"Impact of disease progression status on time to deterioration of patient reported health related quality of life in first-line ER+, HER2\u2013advanced\/metastatic breast cancer patients in the PALOMA-2 study","volume":"36","author":"Harbeck","year":"2017","journal-title":"Breast"},{"issue":"4","key":"10.1093\/annonc\/mdy192_bb0170","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1093\/annonc\/mdy192_bb0175","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdy192_bb0180","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/annonc\/mdw139","article-title":"Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial","volume":"27","author":"Harbeck","year":"2016","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdy192_bb0185","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1634\/theoncologist.2016-0097","article-title":"Palbociclib in combination with fulvestrant in women with hormone receptor-positive\/HER2-negative advanced breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, phase III study (PALOMA-3)","volume":"21","author":"Verma","year":"2016","journal-title":"Oncologist"},{"issue":"17","key":"10.1093\/annonc\/mdy192_bb0190","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-17-0754","article-title":"MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+\/HER2- metastatic breast cancer","volume":"23","author":"Dickler","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"4 Suppl","key":"10.1093\/annonc\/mdy192_bb0195","first-page":"11","article-title":"Abstract P6-11-12: subgroup analysis by prior treatment and disease burden in MONARCH 1: a phase 2 study of monotherapy abemaciclib, a CDK4 & 6 inhibitor, in patients with HR+\/HER2- metastatic breast cancer (MBC) following chemotherapy","volume":"77","author":"Rugo","year":"2017","journal-title":"Cancer Res"},{"issue":"15 Suppl","key":"10.1093\/annonc\/mdy192_bb0200","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1200\/JCO.2017.35.15_suppl.1019","article-title":"Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer","volume":"35","author":"Tolaney","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1093\/annonc\/mdy192_bb0205","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1093\/annonc\/mdu456","article-title":"Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2","volume":"25","author":"Piccart","year":"2014","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1093\/annonc\/mdy192_bb0210","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","article-title":"Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study","volume":"30","author":"Bachelot","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy192_bb0215","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0060","article-title":"Everolimus plus endocrine therapy in the first- and second-line setting for postmenopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (BOLERO-4): an open-label, single-arm, phase 2 trial","author":"Royce","year":"2018","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdy192_bb0220","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.clbc.2013.08.011","article-title":"Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2","volume":"13","author":"Pritchard","year":"2013","journal-title":"Clin Breast Cancer"},{"issue":"15 Suppl","key":"10.1093\/annonc\/mdy192_bb0225","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1200\/JCO.2017.35.15_suppl.1004","article-title":"Phase III study of lapatinib (L) plus trastuzumab (T) and aromatase inhibitor (AI) vs T+AI vs L+AI in postmenopausal women (PMW) with HER2+, HR+ metastatic breast cancer (MBC): ALTERNATIVE","volume":"35","author":"Gradishar","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdy192_bb0230","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","volume":"14","author":"Swain","year":"2013","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1093\/annonc\/mdy192_bb0235","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1158\/1078-0432.CCR-12-3327","article-title":"Phase II trial of bicalutamide in patients with androgen receptor\u2013positive, estrogen receptor-negative metastatic breast cancer","volume":"19","author":"Gucalp","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1093\/annonc\/mdy192_bb0240","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/annonc\/mdw067","article-title":"A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)","volume":"27","author":"Bonnefoi","year":"2016","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdy192_bb0245","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2016.71.3495","article-title":"Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer","volume":"36","author":"Traina","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdy192_bb0250","doi-asserted-by":"crossref","first-page":"v103","DOI":"10.1093\/annonc\/mdw327","article-title":"Prevention and screening in BRCA mutation carriers and other breast\/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening","volume":"27","author":"Paluch-Shimon","year":"2016","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1093\/annonc\/mdy192_bb0255","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/14737140.2017.1374175","article-title":"Genetic testing in women with breast cancer: implications for treatment","volume":"17","author":"Paterson","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"10.1093\/annonc\/mdy192_bb0260","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/jamasurg.2017.0552","article-title":"The role of genetic testing in patients with breast cancer: a review","volume":"152","author":"Valencia","year":"2017","journal-title":"JAMA Surg"},{"issue":"6","key":"10.1093\/annonc\/mdy192_bb0265","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"issue":"15 Suppl","key":"10.1093\/annonc\/mdy192_bb0270","doi-asserted-by":"crossref","first-page":"TPS1107","DOI":"10.1200\/jco.2015.33.15_suppl.tps1107","article-title":"A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and\/or metastatic breast cancer (EMBRACA)","volume":"33","author":"Litton","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdy192_bb0275","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1470-2045(13)70611-9","article-title":"Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01\/UNICANCER)","volume":"15","author":"Andr\u00e9","year":"2014","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1093\/annonc\/mdy192_bb0280","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial","volume":"16","author":"Le Tourneau","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdy192_bb0285","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.ijrobp.2009.12.061","article-title":"Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system","volume":"79","author":"Levin","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1093\/annonc\/mdy192_bb0290","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11060-009-9801-z","article-title":"Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis","volume":"94","author":"Torcuator","year":"2009","journal-title":"J Neurooncol"},{"issue":"9","key":"10.1093\/annonc\/mdy192_bb0295","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/neuonc\/not085","article-title":"Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery","volume":"15","author":"Boothe","year":"2013","journal-title":"Neuro Oncol"},{"key":"10.1093\/annonc\/mdy192_bb0300","doi-asserted-by":"crossref","first-page":"25.","DOI":"10.1186\/2047-783X-17-25","article-title":"Reversal of cerebral radiation necrosis with bevacizumab treatment in 17 Chinese patients","volume":"17","author":"Wang","year":"2012","journal-title":"Eur J Med Res"},{"issue":"2","key":"10.1093\/annonc\/mdy192_bb0305","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11060-014-1391-8","article-title":"An analysis of radiation necrosis of the central nervous system treated with bevacizumab","volume":"117","author":"Tye","year":"2014","journal-title":"J Neurooncol"},{"issue":"4","key":"10.1093\/annonc\/mdy192_bb0310","doi-asserted-by":"crossref","first-page":"273","DOI":"10.14740\/jocmr2936e","article-title":"Bevacizumab for the treatment of radiation-induced cerebral necrosis: a systematic review of the literature","volume":"9","author":"Delishaj","year":"2017","journal-title":"J Clin Med Res"},{"issue":"1","key":"10.1093\/annonc\/mdy192_bb0315","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.radonc.2011.08.017","article-title":"Preoperative radio-chemotherapy in early breast cancer patients: long-term results of a phase II trial","volume":"102","author":"Bollet","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1093\/annonc\/mdy192_bb0320","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2017.03.027","article-title":"Preoperative radiation therapy: the \u2018new\u2019 targeted breast cancer treatment?","volume":"78","author":"Coles","year":"2017","journal-title":"Eur J Cancer"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdy192_bb0325","doi-asserted-by":"crossref","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","article-title":"MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila","year":"2016","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdy192_bb0330","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S1470-2045(17)30109-2","article-title":"Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial","volume":"18","author":"Rugo","year":"2017","journal-title":"Lancet Oncol"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdy192_bb0335","doi-asserted-by":"crossref","first-page":"v139","DOI":"10.1093\/annonc\/mdv202","article-title":"Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up","volume":"26","author":"Peterson","year":"2015","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdy192_bb0340","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s00520-018-4054-z","article-title":"Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer","volume":"26","author":"Bun","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1093\/annonc\/mdy192_bb0345","series-title":"The Target System\u2014Approach to Assessment, Grading, and Management of Dermatological & Mucosal Side Effects of Targeted Anticancer Therapies","author":"Boers-Doets","year":"2014"},{"issue":"11","key":"10.1093\/annonc\/mdy192_bb0350","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1634\/theoncologist.2011-0115","article-title":"Clinical presentation and management of hand\u2013foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer","volume":"16","author":"Gomez","year":"2011","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdy192_bb0355","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.breast.2016.04.012","article-title":"Complementary and integrative medicine for breast cancer patients - evidence based practical recommendations","volume":"28","author":"Witt","year":"2016","journal-title":"Breast"},{"issue":"52","key":"10.1093\/annonc\/mdy192_bb0360","first-page":"3","article-title":"A comprehensive definition for integrative oncology","volume":"2017","author":"Witt","year":"2017","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1093\/annonc\/mdy192_bb0365","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/S0960-9776(17)30754-3","article-title":"OR135\u2014effect of exercise on cardiovascular fitness and quality of life outcomes in advanced breast cancer patients","volume":"36","author":"Oliveira","year":"2017","journal-title":"Breast"},{"issue":"3","key":"10.1093\/annonc\/mdy192_bb0370","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000477575","article-title":"AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2017","volume":"12","author":"Liedtke","year":"2017","journal-title":"Breast Care (Basel)"},{"key":"10.1093\/annonc\/mdy192_bb0375","unstructured":"ABC Global Alliance ESO initiative. ABC Global Charter 2018; http:\/\/www.abcglobalalliance.org\/wp-content\/uploads\/2018\/06\/ABC-Global-Charter-Booklet-June-2018-Final.pdf (25 June 2018, date last accessed)."}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419341134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419341134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/29\/8\/1634\/25505041\/mdy192.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T21:59:36Z","timestamp":1631829576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419341134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":74,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0923753419341134"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdy192","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}